Cue Biopharma, Inc. (CUE) Stock

Cue Biopharma, Inc. (CUE) is a Healthcare stock trading at $23.96 (as of 2026-08-21), with a market capitalization of $174.06M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic therapeutics that selectively modulate the human immune system, including targets for cancers, chronic infectious diseases, and autoimmune disorders. Its pipeline includes fusion protein and Immuno-STAT programs such as CUE-101 and CUE-100 series (e.g., KRAS G12V), along with receptor-targeted approaches (e.g., CD80 and/or 4-1BBL), and it reports research and development collaborations with Merck Sharp & Dohme and LG Chem Life Sciences.

Understand Cue Biopharma, Inc.: how it makes money

Cue Biopharma is a clinical-stage biopharmaceutical company developing biologic drugs that selectively modulate the human immune system, including its lead candidate CUE-101 (a fusion protein biologic in Phase 1b), and it reports revenue through collaboration arrangements (Collaboration Revenue).

Because the company’s reported revenue is shown as Collaboration Revenue, its near-term economics depend on collaboration activity while its immune-modulating biologic candidates (including CUE-101, CUE-102, and CUE-103) generate clinical data in trials.

Revenue by segment (latest quarter)
Collab$0.0B

Business quality (Weak): Clinical-stage focus with reported Collaboration Revenue at 0.0B and a very negative operating margin, so ongoing trial results and collaboration funding are central to progress, while commercialization timing remains uncertain.

Bull case

  • Objective response and durability metrics are shown for a combination setting: Objective Response Rate (Combination) is 46.0 percent, with Median Progression-Free Survival (Combination) at 5.8 (ratio).
  • Survival-related measures are also provided: Twelve-Month Overall Survival (Combined Positive Score Greater than or Equal to 1, Combination) is 90.0 percent and Median Overall Survival (Combined Positive Score Greater than or Equal to 1, Combination) is 21.8 (ratio).

Bear case

  • No reported revenue in the latest quarter: For the period ending 2026-03-31, revenue is 0.0B and the only segment shown is Collaboration Revenue at 0.0B.
  • Operating profitability is currently deeply negative: Operating margin is -94.1 (for the period ending 2026-03-31), reflecting ongoing loss-making operations.
Valuation — source: SEC EDGAR (first-party)
Price$23.96
Market Cap$174.06M
Price / Book75.35
Price / Sales4.62
FCF Yield-28.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$27.47M
Net Margin-96.9%
Revenue Growth (YoY)166.7%
EPS Growth (YoY)26722.2%
FCF Growth (YoY)742.6%
Financial Health — source: SEC EDGAR
Altman Z-Score75.99 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBleichroeder LP ($1.57M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOUsman Azam
Employees41
CountryUS
IPO Date2018-01-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Korro Bio, Inc. (KRRO)
  • Nkarta, Inc. (NKTX)
  • Tharimmune, Inc. (CNTN)
  • Lifecore Biomedical, Inc. (LFCR)
  • Indaptus Therapeutics, Inc. (INDP)
  • OnKure Therapeutics, Inc. (OKUR)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Assertio Holdings, Inc. (ASRT)
CUE earnings history · CUE institutional & insider holders · CUE KPIs & operating metrics · CUE financials · CUE investor presentations & press releases · CUE SEC filings · CUE peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.